Short communication · 4 Aug 2026
Conference abstractPublished 5 Jul 2018
Fimasartan protect cardiac myocyte damage in ischemic heart diseases
Seoul National University Bundang Hospital, South Korea; Jungwon University, South Korea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Fimasartan is a new angiotensin II receptor antagonist (ARB) with high selectivity for the AT1R subtype. Fimasartan showed superior inhibitory activity in the contraction of isolated rabbit thoracic aorta compared with other ARBs and showed protective effect in acute MI model. Fimasartan significantly reduced the infarct size after ischemia and reperfusion (I/R) injury and prevented mitochondrial dysfunction through inhibition of Ca2+ overload during acute reoxygenation. However, it is unknown whether fimasartan has any protective effect on cardiac remodeling after MI. Angiotensin receptor blocker (ARB) treatment before the onset or during the acute stage of myocardial infarction (MI) mitigates the progression of post-MI cardiac remodeling. We investigated the effect of fimasartan, a new ARB, on cardiac remodeling after MI. Sprague-Dawley rats were assigned in to three groups; surgery only (Sham group, n=8), MI without (MI group, n=11), and MI with fimasartan treatment group (MI+fimasartan group, n=14). MI was induced by permanent ligation of the left anterior descending artery (LAD). Treatment with fimasartan (10 mg/kg) was initiated 24 hours after MI and continued for seven weeks via oral administration. After harvesting the heart, the size of infarct and fibrosis area was lower in MI+fimasartan than MI group. MI+fimasartan group had higher left ventricular ejection fraction (LVEF) (66.3Ã?±12.5% vs. 51.3Ã?±14.8%, P=0.002) and Left ventricular enddiastolic diameter (LVEDD) (9.14Ã?±1.11 mm vs. 9.91Ã?±1.43 mm, P=0.045) than MI group at seven weeks. In microarray analysis, fimasartan treatment dramatically decreased genes related with inflammatory signal and increased those related with lipid metabolism. In addition, mitochondria membrane ion transport and damage response genes were increased. Fimasartan attenuates the left ventricular (LV) remodeling and cardiac dysfunction after MI. Fimasartan may be used to mitigate the progression of heart failure after MI.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical and Experimental Cardiology.
Conference abstract · 15 Jun 2026
Speckle Tracking Echocardiography for Early Identification of Chemotherapy-Induced Cardiotoxicity
Conference abstract · 15 Jun 2026
Coronary CT Angiography as a First-Line Diagnostic Tool for Stable Chest Pain: Clinical Outcomes from a Multicenter Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical and Experimental Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “Dong Ju Choi”
- BylineArticles whose byline prints “Byung-Kwan Lim”
- BylineArticles whose byline prints “Jin Joo Park”
